Insulin medicines: Working
What it is
The product and the job it does, in a short paragraph
Insulin medicines replace or top up the hormone insulin in people with diabetes. They are sold as solutions or suspensions in glass vials, cartridges and pre-filled pens [7][14]. The functional unit is one vial or pen. Human insulin and modified insulin analogues are both counted. Insulin pumps, glucose monitors, bulk insulin as an ingredient, GLP-1 medicines and other diabetes medicines are left out.
as of 2026-11-13
How it works
How it does its job, step by step in plain words
Insulin is a peptide hormone [6]. The medicine is injected under the skin [5]. Some products act fast, to cover meals, and others act over many hours or, in the newest product on sale in India, a week [10]. Human insulin has the same amino-acid sequence as the natural hormone; analogues are modified molecules, the first rapid one being Humalog in 1996 [5]. The medicine is made by microbes carrying the human gene [3][6]. Vials are drawn into a syringe, while pens carry a cartridge and a dose dial. The twin technology page explains the medical use.
as of 2026-11-13
Key specifications
The numbers that describe it, each with unit, variant, year and source
| Spec | Value | Unit | Variant | Year | Source |
|---|---|---|---|---|---|
| Strength of the four WHO-prequalified human insulins in vials and cartridges (Novo Nordisk A/S) | 100 | IU per ml | Human | 2022 | [7] |
| Time the prequalified human insulins may be kept at up to 30 degrees C before opening | 4 | weeks | Human | 2022 | [7] |
| Pens used by a patient in a year on once-daily basal insulin (France, modelled by authors from Novo Nordisk and Putnam) | 22 | pens per year | – | 2024 | [14] |
| Pens used by a patient in a year on once-weekly basal insulin (France, modelled by authors from Novo Nordisk and Putnam) | 5 | pens per year | – | 2024 | [14] |
| Size of the larger pen of the once-weekly insulin Awiqli sold in India (1 ml and 3 ml pens, as reported) | 3 | ml (larger pen) | Analogue | 2026 | [10] |
as of 2026-11-13
Variants
The variants whose make-up or footprint differs a lot, what defines each and its share of units
| Variant | Defining spec | Year | Source |
|---|---|---|---|
| Human | Same amino-acid sequence as the natural hormone; made by microbes since the FDA approved Humulin in 1982 [3][5] | 1982 | [3][5] |
| Analogue | Modified molecule (rapid, long or once-weekly acting); the first rapid analogue, Humalog, dates from 1996, and once-weekly basal insulins are analogues too; WHO says analogues cost at least 1.5 times human insulins [1][5] | 1996 | [1][5] |
as of 2026-11-13
Limits
The physical limits set by science and the engineering limits of today's design, with today's value
| Limit | Kind | Limit | Today | Unit | Source |
|---|---|---|---|---|---|
| Time out of refrigeration allowed before opening, human insulin vials and cartridges (Novo Nordisk, WHO-prequalified) | Engineering | 4 | 4 | weeks at up to 30 degrees C | [7] |
| Time between basal insulin doses: once-weekly products against once-daily | Engineering | – | 7 | days (weekly product, India 2026; no limit stated) | [10] |
as of 2026-11-13
Science it relies on
The science principles it works by or is limited by
Relies on- Hormones Insulin is a hormone: it carries a message from the blood to cells that tells them to take up sugar.
- Microbial fermentation Novo Nordisk uses yeast to make the recombinant insulin precursor; other makers use E. coli bacteria [6].
as of 2026-11-13
Sources
- New WHO report maps barriers to insulin availability and suggests actions to promote universal access World Health Organization, 2021, news item of 12 November 2021
- Insulin Development and Commercialization American Chemical Society (National Historic Chemical Landmark), 2023, landmark booklet, © 2023 American Chemical Society
- 100 Years since the Discovery of Insulin, from Its Discovery to the Insulins of the Future Biomedicines (MDPI), on PubMed Central, 2024
- Insulin: Recombinant Production, Sustainability, and Chemistry Oxford Global (article by Tom Cohen on a presentation by Thomas Høeg-Jensen, Scientific Director at Novo Nordisk), 2023, page of 25 April 2023
- First human insulins prequalified World Health Organization, Prequalification of Medical Products, 2022, news item of 28 September 2022
- India 2030: Who Supplies the Next 10 Million? BioSpectrum India (Ankit Kankar), 2026, article of 1 November 2026
- Environmental Impact of Switching from Daily to Weekly Basal Insulin Administration in France ISPOR Europe 2024 abstract EE212 (Bellier L, Antier C, Soggiu M, Virely N, Laporte L, Sivignon M, Kind B; affiliations Putnam, Paris, and Novo Nordisk, Paris), Value in Health 27(12) S2, 2024